Evolution of Predictive Diagnostics: From Companion to Complementary and Immunohistochemistry to Next Generation Sequencing

1 NSH Contact Hour(s)

(based on 5 customer ratings)

Eligible members save $5. If you're a member, enter your member number here to get the member price »

Julie Jay, PhD, International Product Manager, Companion Diagnostics, Ventana Medical Systems, Inc., Tucson, AZ

This webinar will present an overview of the evolution of predictive diagnostics from the perspective of the regulatory terminology, the technology platforms and the utilization of biomarkers to aid in patient treatment decisions. Predictive diagnostics include companion diagnostics that select patients eligible for treatment as well as complementary diagnostics which provide information about how well a patient may respond to the therapy. Predictive diagnostics have utilized IHC, ISH as well as PCR, and NGS predictive diagnostics assays are currently under development. Due the fact that protein and gene targets inform drug development to enable clinical success, predictive diagnostics will play an increasing role in patient care.

See more courses in: General Histology; Immunohistochemistry; Molecular

Continuing Education Credits

NSH Contact Hours (acceptable for AMT, ASCP, and state recertification): 1 hour(s)
Course number WEB0117
Florida Board of Clinical Laboratory Personnel Credit Hours - Immunohistochemistry/Advanced Histologic Techniques: 1 hour(s)
Florida Board of Clinical Laboratory Personnel Credit Hours - General (Clinical Chemistry/UA/Toxicology): 0 hour(s)
Course number 20-577357, approved through 1/31/2019

Objectives

  • Understand the evolution of predictive diagnostics
  • Understand the shift from companion to complimentary
  • Understand what the shift from immunohistochemistry to next generation sequencing will look like

Customer Ratings

(based on 5 customer ratings)

Additional Information

Course Description: This webinar will present an overview of the evolution of predictive diagnostics from the perspective of the regulatory terminology, the technology platforms and the utilization of biomarkers to aid in patient treatment decisions. Predictive diagnostics include companion diagnostics that select patients eligible for treatment as well as complementary diagnostics which provide information about how well a patient may respond to the therapy. Predictive diagnostics have utilized IHC, ISH as well as PCR, and NGS predictive diagnostics assays are currently under development. Due the fact that protein and gene targets inform drug development to enable clinical success, predictive diagnostics will play an increasing role in patient care.
Presenter Bio: Dr. Julie Jay is the International Product Manager for Roche Tissue Diagnostic. She holds a Bachelor’s in Chemistry from Colorado Mason University and a PhD in Pharmaceutics and Pharmaceutics Chemistry from the University of Utah.
Additional Information:  This course was presented in January 2017 as part of the NSH Laboratory Webinar Series

How to Subscribe
Single online course$30
Eligible members save $5
Add to cart
  • Order for instant access through any computer, any browser.
  • No shipping, faxing, or waiting for certificates.
  • Print or save your certificate of completion as soon as you've completed the course.
  • You'll have a full year (365 days) to complete your purchased courses.
Image for OLC 0117



 
Learn.NSH.org's design and platform are provided by MediaLab, Inc.